Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2020
FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer
23 January 2020 - Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 22 Jan 2020
Reimbursement for Repatha to expand treatment options for ASCVD patients
22 January 2020 - Amgen is set to expand treatment options for atherosclerotic cardiovascular disease patients with Repatha, a high-cholesterol treatment, ...
Posted by Michael Wonder on 22 Jan 2020
Roche wins approval for cancer drug Kadcyla in fast-growing China market
23 January 2020 - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another ...
Posted by Michael Wonder on 22 Jan 2020
Merck strengthens Gonal-f portfolio with approval for 150 IU pen in the European Union
22 January 2020 - New Gonal-f 150 IU pen provides additional flexibility and convenience at every stage of the patients’ stimulation ...
Posted by Michael Wonder on 22 Jan 2020
NHS patients denied new lung cancer drug after another NICE deadlock
22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...
Posted by Michael Wonder on 22 Jan 2020
NICE rejects Janssen’s Stelara on cost efficiency grounds
22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...
Posted by Michael Wonder on 21 Jan 2020
FDA approves first treatment for thyroid eye disease
21 January 2020 - Today, the U.S. FDA approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a ...
Posted by Michael Wonder on 21 Jan 2020
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
21 January 2020 - Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b. ...
Posted by Michael Wonder on 21 Jan 2020
European Commission approves Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are transplant eligible
20 January 2020 - Janssen announced today that the European Commission has granted marketing authorisation for Darzalex (daratumumab) in combination with ...
Posted by Michael Wonder on 21 Jan 2020
Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea
20 January 2020 - Sunosi is the only licensed therapy in Europe for the treatment of excessive daytime sleepiness in adults ...
Posted by Michael Wonder on 20 Jan 2020
Novartis announces EU approval of Mayzent (siponimod) for adult patients with secondary progressive multiple sclerosis with active disease
20 January 2020 - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...